Increased Fiber Intake Enhances Clostridia Bacteria and Reduces Clinical Relapse in Patients With Clinically Quiescent Inflammatory Bowel Disease: A Prospective Longitudinal Study

增加膳食纤维摄入量可促进梭状芽孢杆菌增殖并降低临床静止期炎症性肠病患者的临床复发率:一项前瞻性纵向研究

阅读:2

Abstract

BACKGROUND AND AIM: A high-fiber, low-animal-protein, and low-saturated-fat diet may modulate gut dysbiosis and benefit inflammatory bowel disease (IBD). This study investigated the effects of this diet on clinical relapses, fecal calprotectin, and gut microbiota in patients with clinically quiescent IBD. METHODS: Sixty-one patients with IBD were enrolled (23 Crohn's disease and 38 ulcerative colitis). All patients were in clinical remission and had maintained unchanged treatment for at least 2 months. They were advised to increase fiber intake and decrease animal protein and saturated fat consumption. Assessments were performed at baseline, week 6, and every 12 weeks until flare or study completion at 54 weeks. Fecal calprotectin and microbiota were analyzed at baseline and upon study completion. The effect of each dietary component on outcomes was analyzed separately. RESULTS: The cumulative flare rate was 22.6%. Increased fiber intake was significantly associated with a lower incidence of clinical flares. Flare rates were 12.6%, 20.5%, and 46.5% in the increased, unchanged, and decreased fiber intake groups, respectively, with significant differences between the increased and decreased groups (p = 0.03). Fecal calprotectin, however, was not significantly different in those who increased fiber intake compared to those who did not. Microbiota analysis showed a significant increase in the Clostridia class in the increased fiber intake group. CONCLUSIONS: Increasing dietary fiber increased Clostridia class bacteria and was associated with a longer time to flare in patients with clinically quiescent IBD.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。